OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. ("Ginkgo," includ ...

The risks may resolve in a year or so but seizing the opportunities will take longer. When a stock you own is struggling to retain value, it pays to know what new problems might lie awaiting in its future. To have the conviction to retain your shares through a dip, you'll also need to appreciate the upcoming opportunities that might make your patience worth the while. Ginkgo Bioworks (DNA -5.64%) is facing a pair of big risks right now, but it also has a pair of big opportunities that could be enough to tur ...

The company is using artificial intelligence, and planning to help others use AI empowered by its data collection. Ginkgo Bioworks (DNA -5.64%) is a biotech that's going big on artificial intelligence (AI). Between its need to perform core workflows with high efficiency, and its generation of tons of biological and manufacturing data that demand analysis, Ginkgo will likely find AI becoming more important to it over time. That's especially true if it starts selling a key input that other biopharma companies ...

Maravai LifeSciences Holdings, Inc. (MRVI) , through its subsidiaries Cygnus Technologies and TriLink BioTechnologies, has announced the launch of AccuRes Host Cell DNA Quantification Kits. This latest launch blends Cygnus' advanced extraction techniques with TriLink's cutting-edge CleanAmp dNTPs technology. The AccuRes kits offer increased sensitivity and specificity in detecting host cell DNA, ensuring the production of biotherapeutics that meet and exceed the most rigorous regulatory standards. Maravai L ...

In a report released in October 2021, Scorpion Capital alleged Ginkgo Bioworks Holdings Inc of being a "colossal scam", claiming that the company, at a $23 billion valuation, was ridiculously overpriced. Former employees cited in this short report claimed that 9 out of 10 projects launched by the company since its inception have failed. Ginkgo shares crashed 12% on the same day the report was released. Investor sentiment deteriorated further when the Department of Justice launched an investigation into the ...

Its ambitious business model may not be sustainable. Ginkgo Bioworks (DNA -1.81%) stock has had a rough 12 months, falling 88%, and undergoing a reverse stock split on Aug. 20 that left its shares down by around 18% in the aftermath. Depending on which view of the company you subscribe to, things could keep getting worse for shareholders over the next couple of years -- or they could get a lot better. Let's game out a few scenarios so that you can understand whether this stock is worth taking a chance on, o ...

Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro. The PCR-based DNA technologies submitted a validation package to the New York State Department of Health (NYSDOH) to expand the permitted use of its Linea Mpox Virus 1.0 Assay to include both mpox clade I and clade II. The company's validation studies concluded that the Assay's primers and probe have 100% homology to ...

The Good Brigade/DigitalVision via Getty Images In recent years, you won't find many names that have done worse than cell programming and biosecurity company Ginkgo Bioworks (NYSE:DNA). The company has continued to miss lofty revenue growth targets, leading to its shares losing almost all of their value. Now that management is trying to turn things around and two major negative catalysts are behind us, it's time to see if this company can finally get on track. Previous coverage of the name I've been bearish ...

Have shares of the troubled life sciences business fallen too far? To say the past year has been rough for investors in Ginkgo Bioworks (DNA -13.85%) would be an understatement of the highest order. As of Aug 14, shares of the synthetic-biology stock were down by 86% in 2024. A beaten-down price isn't the only way the stock market has signaled low expectations. Ginkgo stock has been trading at a steeply negative enterprise value. It's a debt-free company that finished June with $730 million in cash and cash ...

Efficiency in core processes is set to increase substantially due to AI. As we've all been told, artificial intelligence (AI) is going to disrupt everything in healthcare, from scheduling a doctor's appointment to developing new medicines. But there's a lot more to AI than large language models (LLMs) like ChatGPT. In fact, there's a good chance that AI's impact on biotech will go far beyond what consumer-facing AI applications might imply. Investors will accrue many of the benefits. Here's my predictions f ...